Davi, Frédéric Langerak, Anton W de Septenville, Anne Langlois Kolijn, P Martijn Hengeveld, Paul J Chatzidimitriou, Anastasia Bonfiglio, Silvia Sutton, Lesley-Ann Rosenquist, Richard Ghia, Paolo
...
Published in
Leukemia
Twenty years after landmark publications, there is a consensus that the somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is an important cornerstone for accurate risk stratification and therapeutic decision-making in patients with chronic lymphocytic leukemia (CLL). The IGHV SHM status has traditionally...
Palandri, Francesca Piciocchi, Alfonso De Stefano, Valerio Breccia, Massimo Finazzi, Guido Iurlo, Alessandra Fazi, Paola Soddu, Stefano Martino, Bruno Siragusa, Sergio
...
Published in
Leukemia
Zhu, Jie Yang, Yong Tao, Jin Wang, Shu-Lian Chen, Bo Dai, Jian-Rong Hu, Chen Qi, Shu-Nan Li, Ye-Xiong
Published in
Leukemia
To investigate progression-free survival (PFS) and event-free survival (EFS) as early efficacy endpoints in diffuse large B-cell lymphoma (DLBCL), this systematic review included phase III randomized controlled trials (RCTs), phase II trials, and retrospective studies in newly diagnosed DLBCL receiving rituximab-containing chemotherapy through data...
Zhao, Helong Mendenhall, Michelle Deininger, Michael W.
Published in
Leukemia
Hehlmann, Rüdiger Voskanyan, Astghik Lauseker, Michael Pfirrmann, Markus Kalmanti, Lida Rinaldetti, Sebastien Kohlbrenner, Katharina Haferlach, Claudia Schlegelberger, Brigitte Fabarius, Alice
...
Published in
Leukemia
Dimopoulos, Meletios Weisel, Katja Moreau, Philippe Anderson, Larry D Jr White, Darrell San-Miguel, Jesus Sonneveld, Pieter Engelhardt, Monika Jenner, Matthew Corso, Alessandro
...
Published in
Leukemia
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma previously treated with lenalidomide, including those refractory to lenalidomide. This analysis evaluated outcomes in patients at first relapse...
Qiu, Yi Huang, Suming
Published in
Leukemia
Recent technological advancements and genome-wide studies provide compelling evidence that dynamic chromatin interaction and three-dimensional genome organization in nuclei play an important role in regulating gene expression. Mammalian genomes consist of many small functional domains termed topologically associated domains (TADs), many of them org...
Pützer, S Varghese, L von Jan, J Braun, T Giri, A K Mayer, P Riet, N Timonen, S Oberbeck, S Kuusanmäki, H
...
Published in
Leukemia
Li, Zhenhua Jiang, Nan Lim, Evelyn Huizi Chin, Winnie Hui Ni Lu, Yi Chiew, Kean Hui Kham, Shirley Kow Yin Yang, Wentao Quah, Thuan Chong Lin, Hai Peng
...
Published in
Leukemia
Identifying patient-specific clonal IGH/TCR junctional sequences is critical for minimal residual disease (MRD) monitoring. Conventionally these junctional sequences are identified using laborious Sanger sequencing of excised heteroduplex bands. We found that the IGH is highly expressed in our diagnostic B-cell acute lymphoblastic leukemia (B-ALL) ...
Eide, Christopher A Kurtz, Stephen E Kaempf, Andy Long, Nicola Agarwal, Anupriya Tognon, Cristina E Mori, Motomi Druker, Brian J Chang, Bill H Danilov, Alexey V
...
Published in
Leukemia
Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic l...